Cure Duchenne®

Impact Report 2025

Our vision is our name:

To Cure Duchenne

Dear Friends,

As we enter 2025, we are deeply grateful for your continued support of CureDuchenne. Over the past two decades, your generosity has created a lasting legacy, improving the lives of individuals affected by Duchenne muscular dystrophy and providing them with more years and a better quality of life.

When our son Hawken was diagnosed with Duchenne over 20 years ago, the future seemed bleak. In response, we founded CureDuchenne with a mission to find a cure and advance scientific discoveries from the lab into clinical trials. Thanks to your unwavering commitment, we've made significant strides—**pushing the boundaries of research and improving resources for families and caregivers.**

We are especially proud of our early funding of the company that became Sarepta Therapeutics. In June 2024, Sarepta's gene therapy drug, Elevidys, received FDA approval for treating Duchenne in individuals age 4 and older, including both ambulatory and non-ambulatory patients. And while it will not help everyone, this approval marks a major step forward, advancing life-changing therapies.

This year, we are also excited to see Capricor Therapeutics, Avidity Biosciences, Dyne Therapeutics and Edgewise Therapeutics—all funded by CureDuchenne—report positive data from their clinical trials. **These milestones bring us ever closer to our goal: a future where everyone has a treatment.**

As we continue advancing the search for a cure, we remain committed to improving care for all affected, particularly in underserved communities. We are pleased to see the success of the CureDuchenne Clinic in Greater Dallas, which provides vital care for uninsured and underinsured children and adults, offering services in both English and Spanish.

Your support drives these transformative advancements. Together, we are building a legacy of hope, progress, and opportunity for thousands worldwide.

Debra and Paul Miller

Our Mission

We are committed to improving the lives of everyone affected by Duchenne through accelerating research to find the cure, improving care and empowering the Duchenne community.

2025 Board of Directors

Jeffrey Goffman (Chairperson)
Partner, Webster Equity Partners

TJ Farnsworth
Founder and Chief Executive Officer, Inception Fertility

Chris Finazzo
Chief Commercial Officer, SeaWorld Entertainment

Diane Kemple
Founder, Joy Celebrity Designs and Philanthropist

Martin Lehr
Chief Executive Officer, Context Therapeutics and Independent Director, Praesidia Biologics

David MacInnis
Financial Services Professional and Philanthropist

John Maraganore, Ph.D.
Partner, ARCH Venture Partners; Advisor, Atlas Ventures; Executive Partner, RTW Investments; and Senior Advisor, Blackstone Life Sciences

Nicholas Prytherch, Ed.D.
Managing Partner, MLP Government Affairs

Bob Smith
Biopharmaceutical Executive and former Senior Vice President, Pfizer, Gene Therapy & Rare Disease

Peter Strelow
Co-Chief Operations Officer, Chair of the PIMCO Funds

Tim Sullivan
Founder and former Chief Executive Officer of ActivePDF, Inc., and Philanthropist

Dana W. White
Managing Director, Juno Collective

Ryan Williams
Partner, Athletes First

Understanding Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a progressive muscle-wasting neuromuscular disease. It is the most prevalent and severe form of muscular dystrophy, affecting approximately 1 in every 5,000 male births.

The root cause of Duchenne is genetic mutations that affect the production of dystrophin, a vital muscle protein integral to maintaining muscle health. The absence of dystrophin leads to muscle cell damage and death, starting in the skeletal muscle and eventually leading to heart and respiratory failure.

Children with Duchenne experience significant delays in achieving early developmental milestones, and then progressively lose functions. By the age of 10 to 12, the majority will need a wheelchair for mobility. As they transition into late adolescence, their cardiac and respiratory muscles become severely compromised. Tragically, many individuals with Duchenne do not live past their late twenties.

This disorder is indiscriminate, affecting individuals across all cultural, economic, and social divides.

5

Typically, individuals are diagnosed around 5 years old

12

Most lose the ability to walk before their teenage years

20

Most don't survive beyond their mid-20s

The Impact of Duchenne on the Body

Cure Duchenne®

- Dystrophin abnormalities
- Possible learning and cognitive difficulties

- Decreased heart function
- Cardiomyopathy
- Leads to heart failure

- Weakens diaphragm
- Requires ventilator
- Leads to pneumonia

- Loss of muscle mass
- Weakness
- Inflammation
- Fibrosis

- Brittle and weak

Accelerating the Cure

Venture Philanthropy: A Model of Innovation

CureDuchenne Ventures enables research and development of new therapies in Duchenne by identifying the most promising opportunities and lending support, both via funding and strategic guidance.

Our investment approach allows us to reinvest the profits from successful ventures into the creation of new drug development opportunities. Our robust portfolio of companies and projects spans a diverse array of cutting-edge technologies aimed at targeting the most pressing needs in Duchenne.

THE VENTURES TEAM

Michael G. Kelly, Ph.D.
Chief Scientific Officer

Lianna R. Orlando, Ph.D.
Vice President of Research

Po-Ting Liu, Ph.D.
Ventures Associate

Where We Go, Funding Follows



CureDuchenne has a track record of successful investments, and our "stamp of approval" helps the biotech companies (to which we provided early funding) attract subsequent funding from other investors. In over 20 years, we have invested $26 million, paving the way for venture capital firms and pharmaceutical companies to follow our lead and invest an additional $3.65 billion directly into those biotech companies to continue this potentially life-saving research.

CureDuchenne's Investment Timeline

Our portfolio includes a range of early-stage companies that are exploring innovative approaches to treating Duchenne muscular dystrophy. These investments are crucial in supporting the foundational research that can lead to significant breakthroughs. It also includes public companies advancing both early and late-stage clinical trials in gene therapy, next-generation exon skipping and regenerative medicine approaches that are anticipated to receive approval in the coming years.

	Prior to 2015	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
RNA Targeting (Exon Skipping and Nonsense Readthrough)	PTC Therapeutics; Nationwide Children's; PROSENSA (BioMarin); Sarepta Therapeutics				AVIDITY BIOSCIENCES		Dyne Therapeutics; PepGen	entrada Therapeutics		hC Bioscience, Inc.; LUCANAbio; TEVARD BIOSCIENCES	
Gene Therapy/ Gene Editing			Bamboo therapeutics (Pfizer)	exonics THERAPEUTICS (Vertex)						MyoGene Bio; Insmed	
AAV Delivery					4DMT	CHAMELEON BIOSCIENCES INC; ShapeTX; AskBio				UF University of Florida	
Novel (non-AAV) Gene Delivery							Myosana Therapeutics		code bio; replay; Gennao	DNA nanobots	
Muscle, Heart and Bone Preserving Therapies	ReveraGen BioPharma (Santhera, Catalyst)	Capricor Therapeutics	RASRx; MyoTherix (Phoenicis)				Edgewise THERAPEUTICS; mesentech				

Advancing Our Impact

2024 Investment Achievements

CureDuchenne's early investments in potential groundbreaking therapies made significant progress in 2024, showcasing the long-term impact of donor-supported efforts. These breakthroughs represent key milestones in our mission to cure Duchenne and underscore the impact of strategic, early-stage funding.

ReveraGen Biopharma:

In the first months of 2024, a new steroid, Agamree, became available for individuals with Duchenne. This product, which was originally developed by ReveraGen Biopharma, was approved by the FDA in October 2023. CureDuchenne had provided funding to ReveraGen Biopharma in 2011. The drug, which is thought to have fewer side effects than other steroids, is now available in the US via Catalyst Pharmaceuticals, and in Europe via Santhera Pharmaceuticals.

Sarepta Therapeutics:

In 2010, CureDuchenne provided a grant to the company that went on to become Sarepta Therapeutics at a critical time for the company, and thus had an important role enabling Sarepta to become the company it is today.

In July of 2024, Sarepta announced that the FDA granted full approval of Elevidys, Sarepta's micro-dystrophin gene therapy product, for ambulatory individuals with Duchenne. Moreover, Elevidys was granted approval via the accelerated pathway for non-ambulatory individuals with Duchenne.

Capricor Therapeutics:

CureDuchenne's 2015 investment in Capricor Therapeutics has helped to deliver major advancements. In 2024, Capricor announced their intent to file for full FDA approval of Deramiocel for the treatment of Duchenne muscular dystrophy cardiomyopathy based on existing data from the Phase 2 HOPE-2 and HOPE-2 open label extension trials and natural history cardiac data. The full submission is expected by year-end 2024. If approved, Deramiocel will be the first treatment to specifically treat Duchenne cardiomyopathy.

Capricor is also working to expand Deramiocel's label to address Duchenne skeletal muscle myopathy, further broadening its impact.

Avidity Biosciences:

CureDuchenne's 2018 investment in Avidity Biosciences also delivered positive results in 2024 from the EXPLORE44 trial. Their exon-skipping agent, AOC 1044 (Delpacibart zotadirsen or del-zota), designed to skip exon 44 of the dystrophin gene demonstrated unprecedented levels of exon skipping and dystrophin production in patients. This was accompanied by a reduction in creatine kinase levels to near normal values. Patients received 5mg/kg of AOC 1044 dosed every six weeks for four months.

- *Statistically significant 37 percent increase in exon 44 skipping and up to 66 percent skipping in some individuals.*
- *Statistically significant increase of 25 percent of normal in dystrophin production and restored total dystrophin up to 54 percent of normal.*
- *Creatine kinase levels reduced to near normal with greater than 80 percent reduction compared to baseline.*

These data are very encouraging as children and adults living with Duchenne muscular dystrophy mutations amenable to exon 44 skipping are still in need of targeted treatment options to address this debilitating disease. This approach (if approved) is expected to treated approximately six percent of Duchenne patients.

Dyne Therapeutics:

CureDuchenne's 2020 investment in Dyne Therapeutics continues to advance, with Dyne reporting in 2024 positive data from their Phase 1/2 trial of DYNE-251, targeting individuals amenable to exon 51 skipping. Key findings include:

- *Patients were dosed at 20 mk/kg every four weeks and DYNE-251 demonstrated a favorable safety profile.*
- *Increased dystrophin expression: 3.7 percent unadjusted, 8.72 percent adjusted for muscle content.*
- *Meaningful functional improvements were observed in all patients treated for six months.*

Dyne plans to pursue FDA accelerated approval, which could bring these much-needed treatment options to patients sooner. This approach (if approved) will treat approximately 11 percent of Duchenne patients.

Edgewise Therapeutics:

CureDuchenne's 2019 investment in Edgewise Therapeutics has also made significant advances in 2024 for its muscle stabilizing agent, sevasemten. This experimental treatment is applicable to all individuals independent of their genetic mutation, and Edgewise is currently conducting separate Phase 2 trials in both Duchenne and Becker muscular dystrophy. CureDuchenne is very proud of this investment, and, if approved, it would be the first therapeutic treatment for individuals with Becker muscular dystrophy.

Also, as sevasemten acts via a completely different mechanism than other drugs used in Duchenne, sevasemten could be used in combination with other therapies as well. In fact, Edgewise is including in their clinical trials individuals who are on exon-skipping therapies, or have received micro-dystrophin gene therapy. We expect to see more data from Edgewise's clinical trials in the coming months.

Progress That Matters

What This Momentum Means for the Duchenne Community

These developments provide new treatment options for more individuals with Duchenne. Some approaches target previously under-addressed aspects of the disease, such as the dilated cardiomyopathy that occurs as patients reach their mid-teens. Some approaches, like gene therapy, aim to treat Duchenne patients regardless of their genetic mutation, while others, such as exon skipping, are mutation-specific and designed for subsets of patients.

These advancements clearly demonstrate how early investments can yield long-term results. CureDuchenne's venture philanthropy model—reinvesting 100 percent of returns into future research and programs serving families—ensures that each donation has a lasting and multiplying effect, driving both scientific progress and critical support for the Duchenne community.

Our supporters are not just helping fund today's breakthroughs—they are creating a legacy that will impact future generations. These 2024 advancements highlight the ripple effect of their generosity, proving that together, we are moving closer to our goal: finding a cure for Duchenne.



Our track record speaks for itself:

- *Provided early funding to the first FDA-approved Duchenne drug.*
- *Supported companies responsible for six of the eight FDA-approved drugs for Duchenne.*
- *Invested more than $26M in 50 different research projects, including investments in 29 companies.*
- *Funded 18 research projects that have advanced to human clinical trials, with more starting soon.*
- *Catalyzed over $3.6B in follow-on investments from venture capital, biotech, and pharmaceutical companies to advance Duchenne therapies.*

Advancing the Future of Duchenne Care and Research

Championing Newborn Screening for Duchenne Nationwide

CureDuchenne is proud to champion efforts to implement newborn screening for Duchenne muscular dystrophy (DMD) across the U.S., enabling early diagnosis and access to treatments that preserve muscle strength and delay disease progression. Through our program at Brigham and Women's Hospital in Boston, MA, led by Dr. Richard Parad, CureDuchenne contributed critical data for the national inclusion of DMD in the Recommended Uniform Screening Panel (RUSP).

Although this program has concluded, we look forward to publishing final data, including findings on multiple female carriers identified through screening. While awaiting a decision from the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), expected by May 2025, we continue to support state initiatives, including Massachusetts, New York, Ohio, Illinois, and Minnesota, which now require DMD screening. As more states consider legislation, CureDuchenne remains dedicated to ensuring early intervention for all children with Duchenne.

Cure Duchenne LINK

CureDuchenne Link: Connecting Families and Researchers to Accelerate Progress

CureDuchenne Link is a vital resource in our mission to cure Duchenne while streamlining research and easing the burden on families. This year, CureDuchenne Link achieved key milestones:

- *Research Expansion: Supported five research collaborations with biotech and pharmaceutical partners, including BioMarin.*
- *Enhanced Accessibility: Now fully bilingual, offering seamless access in English and Spanish through its partnership with The Akari Foundation.*
- *Streamlined Data Integration: Continued collaboration with PicnicHealth provides researchers with real-world patient data, accelerating progress.*
- *Increased Participation Access: Expanded to 12 active research sites in collaboration with TRiNDS, making participation easier and more inclusive.*

As a centralized biobank, CureDuchenne Link is open to all individuals with Duchenne or Becker, regardless of mutation or mobility status. It collects and preserves high-quality data and biosamples, giving researchers immediate access to critical resources and reducing delays.

This unique platform minimizes the need for families to provide data repeatedly by serving current and future studies.

CureDuchenne Link connects families and researchers, ensuring biosamples are maximized for impact. By simplifying participation and fostering innovation, it accelerates the path toward a cure.

Together, we are making meaningful progress and offering hope to those impacted by Duchenne and Becker muscular dystrophy.

> *"Our partnership will give members of the muscular dystrophy community the peace of mind that they can easily access and share their complete medical record with their entire care team while helping advance research to facilitate the next generation of therapies for muscular dystrophy."*
>
> —**Noga Leviner,** PicnicHealth founder and CEO

Redefining Care

Setting a New Standard of Excellence in Care

Throughout every stage of the Duchenne journey, we stand with families, offering unwavering support, trusted resources, and expert guidance to help them face each challenge with confidence and hope.

CureDuchenne Cares, our interactive education and outreach program, continues to serve as a vital resource for parents, caregivers, physical therapists, and allied health professionals dedicated to supporting patients with Duchenne and Becker muscular dystrophy. For more than 20 years, we have provided comprehensive resources, information, and best practices, improving the quality of life for individuals living with Duchenne. Notably in 2024, CureDuchenne successfully conducted 100 1:1 sessions, ensuring that families and caregivers received expert support tailored to their needs.

CureDuchenne provides resources to families through:

- ***CureDuchenne 1:1:*** CureDuchenne has excelled in providing personalized guidance through its CureDuchenne 1:1 program, offering unbiased information from scientists, physical therapists, family support resource coordinators, and parents.
- ***Caregiver Dinner Sessions:*** Local dinner events where caregivers can connect and build community.
- ***Workshops:*** Day-long educational sessions featuring updates in care and research from experts.
- ***CureDuchenne Advocacy:*** Advancing causes and policies through legislation and education.
- ***Virtual Events:*** Global webinars and online events for education and social connection.
- ***Clinic Busy Bags:*** Resources and activities to support families during lengthy clinic visits.
- ***Medical ID Bracelets:*** Critical wristbands that communicate Duchenne-specific medical details to EMS during emergencies.

> *When our son was diagnosed with Duchenne, we had no idea where to start looking for the best doctors and care. I reached out to CureDuchenne, whose experts talked with us and gave us resources and a personalized checklist to make sure he was getting proper care. I don't know what we would have done without CureDuchenne."*
>
> **—Catalina Rodriguez, mother of a child living with Duchenne**

Leading the Way in Professional Education for Duchenne Care

The CureDuchenne Professional Education Program offers both Physical Therapy (PT) and Occupational Therapy (OT) Certification specifically for Duchenne care. This unique program is designed to enhance the quality of life and independence of individuals with Duchenne, focusing on prolonging mobility and slowing disease progression. It remains the only program of its kind to offer certified training tailored to Duchenne care.

In 2024, CureDuchenne has expanded its reach, supporting the ongoing education of over 108 CureDuchenne Certified Physical and Occupational Therapists across the United States and offering training internationally in countries from Uganda to China. With recent grant funding, CureDuchenne is developing additional programs for healthcare professionals and families affected by Duchenne, increasing accessibility to vital training worldwide.

THE PT TEAM

Doug Levine, PT
Physical Therapist

Jennifer Wallace, PT
Physical Therapist

OUR IMPACT

118 *Physical and occupational therapists educated in 2024*

1,755 *Course attendees since the program's inception*

Our Global Reach

CureDuchenne provides community engagement and care programming initiatives internationally by identifying areas of need and underserved areas, assessing access to education, healthcare and resources, research progress and the availability of medical equipment. Educational programs have been provided both in-person and virtually in diverse countries, including **North America: the United States, Canada; Europe: England, Italy, Hungary, Ukraine, Russia; Asia: India, Nepal, China; Africa: Uganda; and Oceania: Australia.** The CureDuchenne team was able to reach more than 300 healthcare providers and families affected by Duchenne in person during the 2024 programs and countless more with the social media awareness campaign partnerships.



The CureDuchenne Clinic Delivers Life-Changing Care

PICTURED: *4-year-old Adrian Martinez Colón and his family traveled from Puerto Rico to receive a groundbreaking gene therapy treatment at the CureDuchenne Clinic.*

The CureDuchenne Clinic at the Neurology & Neuromuscular Care Center, led by Dr. Diana Castro, continues to deliver high-quality, specialized care for patients with Duchenne and Becker muscular dystrophy, from childhood through adulthood. Open to all, the clinic never denies care due to lack of insurance and provides services in both English and Spanish. In 2024 alone, the clinic served over 200 Duchenne patients, a testament to its essential role in the community. Services include neurology, cardiology, pulmonology, nutrition, physical therapy, diagnostics, and durable medical equipment. Due to increasing demand, plans are underway to expand the clinic to a larger space in 2025.

Texas has the highest percentage of uninsured residents in the country, with Dallas ranking as the second least-insured major city. Insurance disparities are significant, with nearly 38 percent of Hispanic residents uninsured—almost double the state average.





> *CureDuchenne was the only foundation that stepped up to support us from the very beginning, providing the means to care for over 200 patients. Without them, this clinic wouldn't exist."*
>
> **—Diana Castro, MD, Board Certified Neurologist and Neuromuscular Physician, Founder and Director, Neurology and Neuromuscular Care Center**

Building Community

FUTURES National Conference 2024

The CureDuchenne FUTURES National Conference is an annual event focused on bringing education, connection, and hope to the entire Duchenne community. This year's theme was BRIGHT FUTURES, placing importance on the acceleration of critical research, improvement of care and quality of life for all, and fostering a community that supports one another and takes on the future together.

OUR IMPACT

716 **Total attendees**
(633 in-person, 83 virtual)

60 **Total families that received travel assistance**
(90 children, 120 adults)

> *"The CureDuchenne FUTURES conference lifted a five-year weight of doubt, replacing it with hope and optimism that my son can have a fulfilling life beyond childhood."*
>
> **—Kris Horne, father of child living with Duchenne**

Stronger Together: A Year of Connection and Care

Duchenne Family Workshops and Dinner Sessions

In 2024, CureDuchenne's Family Workshops and Dinner Sessions created vital spaces for education, support, and connection within the Duchenne community. Across 18 locations, eight workshops and 10 dinner sessions welcomed more than 214 family members, providing critical resources and a sense of belonging.

Each event offered more than information—it provided hope. Families learned from healthcare providers, advocates, and industry leaders about advancements in care, day-to-day challenges, and the latest in Duchenne research. Dinner Sessions added a unique touch, offering a relaxed setting where families could share experiences and find strength in community.

These gatherings also connected families with key stakeholders, fostering collaboration to improve care and outcomes. Whether it was a newly diagnosed parent or a long-time advocate, every participant left with new knowledge and renewed encouragement.

As our community grows, so does our commitment to these events. In 2025, we aim to expand their reach and continue strengthening the ties that make the Duchenne community so resilient.

> *CureDuchenne community events are truly special. They bring families, researchers, and advocates together, creating connections and sharing hope. Every time I attend, I leave inspired to do more."*
>
> **—Melanie Burton Sanford, mother of a child living with Duchenne**

The Fundraising That Fuels Our Impact

Getzlaf Golf Shootout Celebrates 14 Years

The Getzlaf Golf Shootout continues to stand as a shining example of unwavering community support, bringing together elite athletes, influential figures, and community leaders to champion the mission of CureDuchenne. This year marked a heartfelt transition as we celebrated the 14th annual event, bidding farewell to our longtime host, NHL All-Star and retired Anaheim Ducks captain **Ryan Getzlaf**, and welcoming **Troy Terry** to carry forward the legacy of leadership.

Over the years, the event has raised millions to fund early-stage research and advance new therapies for Duchenne muscular dystrophy. Held once again at the picturesque Monarch Beach Golf Links in Dana Point, California, this year's tournament was truly unforgettable. A heartfelt thank you to every participant, family, and sponsor who made it possible.

TOTAL RAISED
$6.3m

The Napa Wine Series: A Toast to Progress

The Napa Wine Series continues to bring the spirit of Napa Valley to cities across the U.S., all in support of CureDuchenne. These distinguished events feature grand tastings with Napa's finest wineries and vintner-hosted dinners curated by renowned chefs.

Since its debut in 2015 with the flagship Napa in Newport, the series has become a celebrated experience for wine enthusiasts, blending world-class wines with a meaningful mission. In 2025, the series will return to sunny Florida with Napa in Miami, uniting another vibrant community to savor the best of Napa Valley while advancing CureDuchenne's vital work.

TOTAL RAISED
$13.9m



> *Celebrating 10 years of Napa in Newport is a testament to the collective spirit of the Napa Valley vintners and our shared commitment to CureDuchenne's important cause. It's an honor to contribute to a future where Duchenne muscular dystrophy is not only treatable, but curable."*
>
> **—Robin and Michelle Baggett, Alpha Omega Winery, 2024 Napa in Newport Honored Vintner Chairs**

Ladies Luncheon Newport Beach: Where Style Meets Purpose

The inaugural Ladies Luncheon Newport Beach debuted on Tuesday, October 15, 2024, at the stunning Shady Canyon Golf Club, bringing together a sophisticated crowd for an unforgettable afternoon of fashion, food, and inspiration.

Guests enjoyed an exclusive preview of Monique Lhuillier's 2025 collection in a luxury fashion presentation produced and sponsored by South Coast Plaza. Alongside the glamour, attendees heard from CureDuchenne's Chief Scientific Officer, Dr. Michael Kelly, who shared groundbreaking insights on how their support drives progress in the search for a cure for Duchenne muscular dystrophy.

This remarkable event wasn't just a celebration of elegance—it was a powerful step toward advancing CureDuchenne's mission, proving that style and purpose can create lasting impact.

TOTAL RAISED
$88k

> *"There were no approved drugs or clinical trials when CureDuchenne started, and today, some of the clinical trials we're considering for Rocco exist because of their early funding efforts."*
>
> **—Karyn Blosil, mother of 6-year-old Rocco, speaking at Ladies Luncheon Newport Beach**

Champions of Change: Driving Progress for Duchenne

CureDuchenne Champions and community partners continue to host impactful fundraising events, both big and small, across the country to support CureDuchenne's mission. From community gatherings to large-scale events, these efforts fuel progress in advancing research and care. Highlighted in the next few pages are a few standout events from 2024.

OUR IMPACT

17 *Number of Champion-led events in 2024*

$1.2m *Total raised in 2024*

15th Annual Champions to CureDuchenne Gala
Austin, TX

Champions to CureDuchenne is an annual fundraising gala hosted by the Revell family, whose two sons live with Duchenne, that brings together Austin's finest for a spectacular evening under the stars. The event features gourmet food, cocktails, casino games, and live and silent auctions for a night of fun and purpose.

2024 Amount Raised: Over $400,000

Ladies Luncheon Austin
Austin, TX

2024 Amount Raised: Over $90,000

Champions in Miami
Miami, FL

2024 Amount Raised: Over $390,000

Dealing for Duchenne San Antonio
San Antonio, TX

2024 Amount Raised: Over $125,000

Calves to Cure
Billings, MT

2024 Amount Raised: Over $34,000

Champions in Dallas
Dallas, TX

2024 Amount Raised: Over $101,000

Drive for Duchenne
Newport Beach, CA

2024 Amount Raised: Over $6,000

Sawyer's Rhode to the Cure Quizzo
Township of Haddon, NJ

2024 Amount Raised: Over $7,200

Scott's Striders - Meat Raffle Fundraiser
Warsaw, NY

2024 Amount Raised: Over $20,000

Cali-RAD (Reggae Against Duchenne)
San Diego, CA

2024 Amount Raised: $8,600

Hunter's Heart 5K
Los Angeles, CA

2024 Amount Raised: $5,000

Beneficiary Events

Mack, Jack & McConaughey
Austin, TX

Mack, Jack & McConaughey (MJ&M) is a philanthropic event founded by Mack Brown, Jack Ingram, and Matthew McConaughey, dedicated to empowering children through education, health, and wellness initiatives. CureDuchenne is honored to be a beneficiary, supporting groundbreaking research and care for boys living with Duchenne muscular dystrophy. Through MJ&M's generosity, we are one step closer to finding a cure and giving these boys a brighter future.

2024 Amount Raised: Over $1.5 million

Knoxville Brewfest
Knoxville, TN

Knoxville Brewfest is an annual celebration of craft beer, bringing together local and regional breweries for a day of tastings, live entertainment, and community fun in downtown Knoxville. Over the past 12 years, the event has raised more than $225,000 for CureDuchenne, supporting research and awareness efforts to combat Duchenne muscular dystrophy.

2024 Amount Raised: Over $25,000

Austin Marathon
Austin, TX

In 2024, Tim Revell completed his 19th Austin Marathon, raising over $350,000 for CureDuchenne to fund research for Duchenne muscular dystrophy which affects his two sons.

2024 Amount Raised: Over $13,000

Be a part of the cure.
GIVE TODAY!

cureduchenne.org/donate

CureDuchenne.org | 949.872.2552 | info@cureduchenne.org
100 Bayview Cir, Suite 5600, Newport Beach, CA 92660
Federal 501(c)(3) | Tax ID: 20-0299958